Absci, a drug creation company driven by artificial intelligence, announced Wednesday it has started a public offering of $75 million worth of shares of its common stock.
The Vancouver company plans to use the proceeds from the sale to develop its internal assets programs and continue its Integrated Drug Creation platform.
Absci also plans to offer the sales’ underwriters a 30-day option to buy an additional $11.25 million of shares.
Absci trades on the Nasdaq as ABSI. Its stock closed Tuesday at $4.92 per share, up from its closing price of $4.90 per share Monday.
